Keywords: scios, benefits, natrecor, launch, usa, says, fourth-quarter
Scios benefits from Natrecor launch
Article | 18 February 2002
Scios of the USA says that fourth-quarter 2001 revenues trebled toreach $10.5 million, due to the contribution of its recently-launched treatment for ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
